OVERVIEW

The Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment is organized by Omnia Education.

Release Date: 04/01/2025
Expiration Date: 04/01/2026

Description:
The management of alloimmune disorders of pregnancy, notably HDFN and FNAIT, has often centered on maternal immunosuppression using IVIG and/or corticosteroids, direct inutero therapy such as fetal intravascular transfusion, preterm delivery as indicated, and/or treatment of the newborn. A novel form of therapy is now emerging that targets the neonatal Fc receptor (FcRn), with the potential to revolutionize the management of these diseases. Join Drs. William Goodnight and Kara Markham as they evaluate current and emerging approaches to diagnosing and managing HDFN and FNAIT.

Learning Objectives:
After participating in this educational activity, participants should be better able to:

Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on hemolytic disease of the fetus and newborn (HDFN), fetal/neonatal alloimmune thrombocytopenia (FNAIT), and fetal/neonatal neutropenia (NAIN)
Identify current diagnostic and treatment regimens for HDFN, FNAIT, and NAIN
Explain the role of the neonatal Fc receptor pathway as a therapeutic means to address HDFN and FNAIT

ACCREDITATION & CREDITS

Accreditation and Credit Designation Statements:
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Global Learning Collaborative (GLC) designates this activity for .5 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for .5 hour(s)/0.05 CEUs of pharmacy contact hour(s).

This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service.

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for .5 AAPA Category 1 CME credit(s). Approval is valid until April 1, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.

0.5 Credits

0.5 Contact Hours

0.05 CEUs

0.5 Hours

0.5 AAPA

TARGET AUDIENCE

PhysicianNursingPharmacistPhysician AssistantObstetrics and Gynecology PhysiciansNursesOBGYNHealthcare ProvidersPediatricsNurse PractitionersGynaecologist